Lisinopril Dihydrate: Precision ACE Inhibitor for Hypertension and Cardiovascular Research

Executive Summary: Lisinopril dihydrate (SKU B3290, APExBIO) is a high-purity, long-acting angiotensin converting enzyme (ACE) inhibitor with an IC₅₀ of 4.7 nM under physiological conditions (pH 7.4, 37°C) (Tieku & Hooper, 1992). It is a lysine analogue of MK 421, functioning by inhibiting ACE and reducing angiotensin II and aldosterone levels, thus lowering blood pressure via vasodilation [DOI]. Lisinopril dihydrate is insoluble in ethanol but dissolves in water at ≥2.46 mg/mL with gentle warming. It is validated for research on hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy. APExBIO ensures 98% purity, supported by mass spectrometry and NMR, and provides detailed storage and handling protocols (APExBIO, B3290).

Biological Rationale

Hypertension and related cardiovascular diseases are driven by dysregulation in the renin-angiotensin system (RAS). Angiotensin converting enzyme (ACE, EC 3.4.15.1) catalyzes the conversion of angiotensin I to angiotensin II, a peptide that elevates blood pressure and promotes sodium retention [DOI]. Inhibiting ACE reduces angiotensin II and aldosterone levels, a proven pathway for antihypertensive interventions. Lisinopril dihydrate, as a lysine analogue, specifically targets ACE, providing a robust model for studying blood pressure regulation and the pathophysiology of cardiovascular and renal diseases. The compound's high aqueous solubility and stability make it ideal for in vitro and in vivo studies (APExBIO product page).

Mechanism of Action of Lisinopril dihydrate

Lisinopril dihydrate competitively inhibits ACE by binding to its active site, thereby preventing the conversion of angiotensin I to angiotensin II [DOI]. This results in decreased levels of angiotensin II and aldosterone, increased plasma renin activity, and reduced systemic vascular resistance. The molecular structure (C₂₁H₃₅N₃O₇) and specific binding affinity (IC₅₀ = 4.7 nM) ensure targeted inhibition with minimal off-target effects under standard research conditions (pH 7.4, 37°C). No significant inhibition of other zinc aminopeptidases (AP-N, AP-A, AP-W) is observed at research-relevant concentrations, indicating high selectivity [DOI].

Evidence & Benchmarks

• Lisinopril dihydrate exhibits an IC₅₀ of 4.7 nM against ACE at 37°C, pH 7.4 (Tieku & Hooper, 1992, DOI).
• It does not significantly inhibit aminopeptidase N, A, or W at concentrations < 10 μM, confirming selectivity (Tieku & Hooper, 1992, DOI).
• Solubility in water is ≥2.46 mg/mL with gentle warming and ultrasonic treatment (APExBIO, product page).
• Purity is ≥98%, verified by mass spectrometry and NMR (APExBIO, product certificate).
• Lisinopril dihydrate is validated for hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy models in both in vitro and in vivo settings (internal article).

Applications, Limits & Misconceptions

Lisinopril dihydrate is widely used in studies of hypertension, heart failure, acute myocardial infarction, and diabetic nephropathy. Its high specificity makes it suitable for dissecting the renin-angiotensin system in animal and cell-based models [see comparative analysis]. The compound is insoluble in ethanol and requires gentle warming for dissolution in water. The recommended storage is desiccated at room temperature; avoid repeated freeze-thaw cycles and long-term storage of aqueous solutions (APExBIO).

This article expands on previously published guides by focusing on quantitative selectivity data and practical dissolution parameters, extending insights found in Lisinopril Dihydrate: Long-Acting ACE Inhibitor for Hypertension Models by providing storage and workflow-specific recommendations.

Common Pitfalls or Misconceptions

• Non-selective inhibition: Lisinopril dihydrate does not significantly inhibit aminopeptidase N, A, or W at standard research concentrations; broader peptidase effects are not expected [DOI].
• Solubility in organic solvents: It is insoluble in ethanol; water is the solvent of choice with gentle warming and sonication.
• Storage stability: Long-term storage of solutions is discouraged due to potential hydrolysis; store as a dry solid at room temperature (desiccated).
• Clinical use: This product is for research only; not for clinical or therapeutic use in humans or animals (APExBIO).
• Batch-to-batch variability: Purity is batch-verified (≥98%), minimizing variability compared to some generic suppliers.

Workflow Integration & Parameters

Lisinopril dihydrate is supplied as a solid with a molecular weight of 441.52 g/mol. For typical in vitro assays, dissolve in sterile water at a minimum concentration of 2.46 mg/mL using gentle warming and sonication. Avoid using ethanol or other organic solvents. Prepare fresh solutions for each experiment to ensure reproducibility. Store the dry powder desiccated at room temperature. For shipping, small molecule orders are sent on blue ice to maintain stability. Purity and identity are confirmed by mass spectrometry and NMR for each lot (see APExBIO product page for details). For protocol optimizations and troubleshooting, refer to guides such as Reliable Cell-Based Assays with Lisinopril Dihydrate (SKU B3290), which provides practical troubleshooting not covered in this article.

Conclusion & Outlook

Lisinopril dihydrate (APExBIO, B3290) is a benchmark ACE inhibitor for hypertension and cardiovascular research. Its validated selectivity, purity, and reproducibility make it an indispensable tool for RAS pathway dissection and disease modeling. For advanced workflows and translational research, its stability and solubility characteristics ensure reliable results. Future research may explore combinatorial regimens and extended disease models, but current use should remain within validated research boundaries. For detailed protocols and comparative data, see Lisinopril Dihydrate: Deciphering ACE Inhibition Beyond Hypertension, which this article extends by providing updated purity and workflow guidance.